• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 
Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
Read More
Anupam Dalal, MD
Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Comments

Comments are closed.

  • Next Post
  • Previous Post